Concordance of assays designed for the quantification of JAK2V617F: a multicenter study
暂无分享,去创建一个
S. Ellard | J. Jelinek | N. Kröger | R. Herrmann | S. Carillo | R. Skoda | V. Ugo | E. Lippert | F. Girodon | S. Hermouet | J. Prchal | B. Fehse | D. Pietra | C. Marzac | N. S. Reading | M. Hermans | S. Swierczek | M. Mounier | E. Hammond | Céline Richard | K. Hanlon | V. Harrivel | M. Sobas | Marina Migeon | Celine Richard | N. Reading
[1] F. Girodon,et al. Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy , 2008, Haematologica.
[2] P. Johansson,et al. Rapid decline of JAK2V617F levels during hydroxyurea treatment in patients with polycythemia vera and essential thrombocythemia , 2008, Haematologica.
[3] Paola Guglielmelli,et al. JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. , 2007, Blood.
[4] V. Najfeld,et al. Numerical gain and structural rearrangements of JAK2, identified by FISH, characterize both JAK2617V>F-positive and -negative patients with Ph-negative MPD, myelodysplasia, and B-lymphoid neoplasms. , 2007, Experimental hematology.
[5] E. Oger,et al. Prevalence of the JAK2 V617F mutation is low among unselected patients with a first episode of unprovoked venous thromboembolism , 2007, Journal of thrombosis and haemostasis : JTH.
[6] N. Pemmaraju,et al. The quantitative JAK2 V617F neutrophil allele burden does not correlate with thrombotic risk in essential thrombocytosis , 2007, Leukemia.
[7] Paola Guglielmelli,et al. Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. , 2007, Blood.
[8] T. Barbui,et al. Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden , 2007, Leukemia.
[9] Ian James,et al. Quantitative determination of JAK2 V617F by TaqMan: An absolute measure of averaged copies per cell that may be associated with the different types of myeloproliferative disorders. , 2007, The Journal of molecular diagnostics : JMD.
[10] P. Heimann,et al. The JAK2V617F mutation is detectable in granulocyte populations at greater than 2 copies per cell among individuals with myeloproliferative disorders , 2007, Leukemia.
[11] E. Lippert,et al. Comparison of whole blood vs purified blood granulocytes for the detection and quantitation of JAK2V617F , 2007, Leukemia.
[12] N. Kröger,et al. Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis. , 2007, Blood.
[13] R. Fijnheer,et al. A sensitive and reliable semi‐quantitative real‐time PCR assay to detect JAK2 V617F in blood , 2006, Hematological oncology.
[14] E. Lippert,et al. Latent myeloproliferative disorder revealed by the JAK2-V617F mutation and endogenous megakaryocytic colonies in patients with splanchnic vein thrombosis. , 2006, Blood.
[15] G. Massonnet,et al. High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. , 2006, Blood.
[16] R. Kralovics,et al. Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. , 2006, Blood.
[17] M. Cazzola,et al. Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. , 2006, Blood.
[18] W. Vainchenker,et al. Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis , 2006, Leukemia.
[19] E. Estey,et al. JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. , 2005, Blood.
[20] Stefan N. Constantinescu,et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera , 2005, Nature.
[21] Mario Cazzola,et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. , 2005, The New England journal of medicine.
[22] R. Kralovics,et al. Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera. , 2002, Experimental hematology.
[23] S. Schwartz. Myeloproliferative Disorders , 1975, Annals of surgery.
[24] A. Tefferi,et al. Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms , 2008, Leukemia.
[25] J. Jelinek,et al. Polycythemia vera is not initiated by JAK2V617F mutation. , 2007, Experimental hematology.
[26] R. Herrmann,et al. The JAK2 V617F mutation is detectable in granulocyte populations at greater than two copies per cell among individuals with myeloproliferative disorders , 2007, Leukemia.
[27] 松山 智洋. What's going on 造血器腫瘍 A gain-of-function mutation of JAK2 in myeloproliferative disorders. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC. N Engl J Med. 2005; 352: 1779-90. PMID:15858187.--慢性骨髄増殖性疾患においてJAK2遺伝子の変異が高頻度にみられることを示した論文 , 2005 .
[28] H. Cody,et al. A high number of tumor free axillary lymph nodes from patients with lymph node negative breast is associated with poor outcome , 2000, Cancer.